Global Skin Cancer Diagnostics & Therapeutics Market Report 2022-2027: Government Initiatives for Early Detection and Skin Cancer Treatment & Proliferation in R and D Pipelines Driving Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Skin Cancer Diagnostics & Therapeutics Market Research Report by Disease Type (Melanoma and Non-melanoma), Type, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering.

The Global Skin Cancer Diagnostics & Therapeutics Market size was estimated at USD 6,214.44 million in 2021, USD 6,842.50 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10.28% to reach USD 11,184.00 million by 2027.

Market Segmentation & Coverage:

• Based on Disease Type, the market was studied across Melanoma and Non-melanoma.
• Based on Type, the market was studied across Diagnosis and Therapeutics. The Diagnosis is further studied across Blood Tests, Dermatoscopy, Imaging Tests, Lymph Node Biopsy, and Skin Biopsy. The Therapeutics is further studied across Chemotherapy, Non-invasive Therapy, and Surgery.
• Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across Arizona, California, Colorado, Florida, Illinois, Massachusetts, Michigan, Nevada, Ohio, Oregon, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Skin Cancer Diagnostics & Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Market Dynamics

Drivers

• Growing Incidences and Rising Awareness of Skin Cancer Globally
• Rising Government Initiatives for Early Detection and Skin Cancer Treatment
• Proliferation in Research and Development Pipelines for Skin Cancer Diagnostics and Therapeutics

Restraints

• High Cost Associated With the Various Skin Cancer Treatment

Opportunities

• Advancements in Skin Cancer Diagnostics & Therapeutics
• Developments of Skin Cancer Care in Emerging Nations

Challenges

• Side Effects of Radiation Therapy for Skin Cancer

Key Topics Covered:

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Skin Cancer Diagnostics & Therapeutics Market, by Disease Type

7. Skin Cancer Diagnostics & Therapeutics Market, by Type

8. Americas Skin Cancer Diagnostics & Therapeutics Market

9. Asia-Pacific Skin Cancer Diagnostics & Therapeutics Market

10. Europe, Middle East & Africa Skin Cancer Diagnostics & Therapeutics Market

11. Competitive Landscape

12. Company Usability Profiles

13. Appendix

Companies Mentioned

• AB Science
• Abbott Laboratories
• Amgen, Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Castle Biosciences, Inc.
• Daiichi Sankyo Company, Limited
• DermTech
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC
• Merck & Co., Inc.
• NeraCare GmbH
• Novartis AG
• Pfizer Inc.
• Qiagen NV
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/8h92vu

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900